ArticlePathobiology of aging & age related diseases2016
Pathology assessment is necessary to validate translational endpoints in preclinical aging studies.
Article in Pathobiology of aging & age related diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Cellular senescence: a key therapeutic target in aging and diseases.The Journal of clinical investigation · 2022Review
- Heterochronic parabiosis: a valuable tool to investigate cellular senescence and other hallmarks of aging.Aging · 2022Article
- PathoClock and PhysioClock in mice recapitulate human multimorbidity and heterogeneous aging.Aging pathobiology and therapeutics · 2021Article
- The geropathology of organ-specific aging.Journal of translational science · 2021Article
- Heterochronic parabiosis regulates the extent of cellular senescence in multiple tissues.GeroScience · 2020Article
- Development of a Geropathology Grading Platform for nonhuman primates.Aging pathobiology and therapeutics · 2020Article
- Fisetin is a senotherapeutic that extends health and lifespan.EBioMedicine · 2018Article
- Modeling Alzheimer's disease in progeria mice. An age-related concept.Pathobiology of aging & age related diseases · 2018Article
- The potential use of physical resilience to predict healthy aging.Pathobiology of aging & age related diseases · 2018Review
- A New Preclinical Paradigm for Testing Anti-Aging Therapeutics.The journals of gerontology. Series A, Biological sciences and medical sciences · 2017Article
- Self-motivated and stress-response performance assays in mice are age-dependent.Experimental gerontology · 2017Article
- Chronic low-level exposure to the common seafood toxin domoic acid causes cognitive deficits in mice.Harmful algae · 2017Article
- The emerging role of geropathology in preclinical aging studies.Pathobiology of aging & age related diseases · 2017Article
- Guidelines for collection and processing of lungs from aged mice for histological studies.Pathobiology of aging & age related diseases · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The Geropathology Research Network has established a plan to identify and use pathology-based surrogate endpoints for aging intervention in preclinical drug studies to provide a predictable and short-term anti-aging drug response in line with clinical trials. The plan involves pathological assessment of tissues and organs from strains of old mice, by independent pathology groups in a concurrent manner in order to characterize the changes in lesion incidence and severity in response to anti-aging drugs at specific time points. This approach allows for connection with translational endpoints of aging, such as serum factors and physiological parameters, between mice and humans. Preclinical drug testing is a critical component of the plan, designed to shorten testing times from lengthy lifespan studies by comparing lesion grades and composite scores in treated and placebo cohorts at cross-sectional time points. In conclusion, a geropathology-based preclinical testing program is a step toward assuring maximum utilization of translational resources and increasing predictability of efficacy of new or repurposed drugs for clinical aging intervention studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.